Zacks: Analysts Anticipate Accuray Incorporated (ARAY) to Announce -$0.07 EPS
Equities analysts forecast that Accuray Incorporated (NASDAQ:ARAY) will announce ($0.07) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Accuray’s earnings, with the lowest EPS estimate coming in at ($0.09) and the highest estimate coming in at ($0.04). Accuray posted earnings of ($0.12) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 41.7%. The business is scheduled to report its next quarterly earnings results on Thursday, October 26th.
On average, analysts expect that Accuray will report full year earnings of ($0.15) per share for the current fiscal year, with EPS estimates ranging from ($0.19) to ($0.13). For the next fiscal year, analysts forecast that the business will report earnings of ($0.06) per share, with EPS estimates ranging from ($0.08) to ($0.03). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that cover Accuray.
Accuray (NASDAQ:ARAY) last posted its quarterly earnings results on Tuesday, August 22nd. The medical equipment provider reported ($0.06) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.01) by ($0.05). The company had revenue of $112.09 million for the quarter, compared to the consensus estimate of $112.00 million. Accuray had a negative net margin of 7.71% and a negative return on equity of 61.62%. Accuray’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.09) EPS.
Several equities research analysts recently issued reports on the company. BTIG Research reissued a “hold” rating on shares of Accuray in a research note on Thursday, August 24th. Jefferies Group LLC lowered their target price on Accuray from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, August 23rd. Royal Bank Of Canada reissued a “hold” rating and set a $5.00 target price on shares of Accuray in a research note on Thursday, August 24th. Zacks Investment Research cut Accuray from a “hold” rating to a “strong sell” rating in a research note on Monday, July 24th. Finally, BidaskClub cut Accuray from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $5.85.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in Accuray by 4.4% during the 2nd quarter. Vanguard Group Inc. now owns 6,728,919 shares of the medical equipment provider’s stock valued at $31,962,000 after acquiring an additional 281,789 shares during the last quarter. Neuberger Berman Group LLC raised its stake in Accuray by 26.7% during the 1st quarter. Neuberger Berman Group LLC now owns 5,014,941 shares of the medical equipment provider’s stock valued at $23,821,000 after acquiring an additional 1,057,654 shares during the last quarter. Renaissance Technologies LLC raised its stake in Accuray by 2.0% during the 2nd quarter. Renaissance Technologies LLC now owns 4,391,000 shares of the medical equipment provider’s stock valued at $20,857,000 after acquiring an additional 85,400 shares during the last quarter. Lapides Asset Management LLC raised its stake in Accuray by 0.3% during the 2nd quarter. Lapides Asset Management LLC now owns 2,221,300 shares of the medical equipment provider’s stock valued at $10,551,000 after acquiring an additional 7,500 shares during the last quarter. Finally, State Street Corp raised its stake in Accuray by 4.2% during the 2nd quarter. State Street Corp now owns 1,700,442 shares of the medical equipment provider’s stock valued at $8,079,000 after acquiring an additional 67,983 shares during the last quarter. 76.67% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Zacks: Analysts Anticipate Accuray Incorporated (ARAY) to Announce -$0.07 EPS” was published by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/09/16/zacks-analysts-anticipate-accuray-incorporated-aray-to-announce-0-07-eps.html.
Shares of Accuray (ARAY) traded up 1.19% during midday trading on Friday, hitting $4.25. 1,687,861 shares of the stock were exchanged. The stock’s market cap is $353.51 million. Accuray has a 52-week low of $3.60 and a 52-week high of $6.39. The firm’s 50 day moving average price is $4.13 and its 200-day moving average price is $4.45.
Accuray Company Profile
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Accuray Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.